Trademark: 97664404
Word
XCELLIT
Status
Registered
Status Code
700
Status Date
Tuesday, February 27, 2024
Serial Number
97664404
Registration Number
7313859
Registration Date
Tuesday, February 27, 2024
Mark Type
5000
Filing Date
Saturday, November 5, 2022
Published for Opposition
Tuesday, December 12, 2023

Trademark Owner History
Galapagos NV - Original Registrant

Classifications
9 recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment
44 Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells
10 Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment
42 Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development
The mark consists of the stylized word "XCELLIT" with the right hand part of the "x" in green, the dot of the "i" in red, and the remainder of the letters in blue.
The color(s) blue, green, and red is/are claimed as a feature of the mark.

Trademark Events
Feb 27, 2024
Notice Of Registration Confirmation Emailed
Feb 27, 2024
Registered-Principal Register
Dec 12, 2023
Official Gazette Publication Confirmation E-Mailed
Dec 12, 2023
Published For Opposition
Nov 22, 2023
Notification Of Notice Of Publication E-Mailed
Nov 6, 2023
Approved For Pub - Principal Register
Nov 6, 2023
Assigned To Examiner
Sep 18, 2023
Teas/Email Correspondence Entered
Sep 18, 2023
Correspondence Received In Law Office
Sep 17, 2023
Teas Response To Office Action Received
Aug 24, 2023
Notification Of Non-Final Action E-Mailed
Aug 24, 2023
Non-Final Action E-Mailed
Aug 24, 2023
Non-Final Action Written
Aug 21, 2023
Assigned To Examiner
Jan 19, 2023
Preliminary/Voluntary Amendment - Entered
Jan 19, 2023
Assigned To Lie
Nov 19, 2022
Teas Voluntary Amendment Received
Nov 23, 2022
New Application Office Supplied Data Entered
Nov 9, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24